clopidogrel
-
CURE Trial: Clopidogrel Plus Aspirin in Patients With NSTEMI/Unstable Angina
The CURE trial was a landmark randomized clinical trial that evaluated whether adding clopidogrel to aspirin improves outcomes in patients with non–ST-elevation acute coronary syndrome, including NSTEMI and unstable angina. The main finding was: clopidogrel plus aspirin reduced cardiovascular death, nonfatal MI, or stroke, but increased major bleeding. Background Patients with NSTEMI or unstable angina…
-
TRITON-TIMI 38 Trial: Prasugrel vs Clopidogrel in Acute Coronary Syndromes
The TRITON-TIMI 38 trial was a major randomized clinical trial comparing prasugrel with clopidogrel in patients with acute coronary syndrome who were scheduled to undergo PCI. The main finding was: prasugrel reduced ischemic cardiovascular events compared with clopidogrel, but increased bleeding risk. Background Patients with acute coronary syndrome are at high risk for recurrent cardiovascular…
-
PLATO Trial: Ticagrelor vs Clopidogrel in Acute Coronary Syndromes
The PLATO trial was a landmark cardiovascular trial comparing ticagrelor with clopidogrel in patients presenting with acute coronary syndrome. The main finding was clear: ticagrelor reduced cardiovascular death, myocardial infarction, or stroke compared with clopidogrel, without a significant increase in major bleeding. Background Patients with acute coronary syndrome, including STEMI and non-STEMI, are at high…
-
DAPT Trial: Twelve vs 30 Months of DAPT After DES
The DAPT trial was a major randomized clinical trial that evaluated whether extending dual antiplatelet therapy beyond 12 months after drug-eluting stent placement improves cardiovascular outcomes. The trial showed that continued dual antiplatelet therapy reduced stent thrombosis and major adverse cardiovascular and cerebrovascular events, but this benefit came at the cost of increased bleeding. Background…